Teva Pharmaceutical Industries Ltd. has obtained final FDA approval for its 150-, 300- and 600-milligram oxcarbazepine tablets. The drug is a generic version of Novartis AG's epilepsy drug Trileptal, which reportedly racked up $594 million in sales for the first nine months of 2007. The approval comes amid an unresolved patent dispute between Teva and Novartis over the drug.

Full Story:

Related Summaries